14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$51.87 (-1.05%)

Volume: 4.907k

Closed: Sep 30, 2022

Hollow Logo Score: -1.611

Enanta Pharmaceuticals Stock Forecast

$51.87 (-1.05%)

Volume: 4.907k

Closed: Sep 30, 2022

Score Hollow Logo -1.611

Enanta Pharmaceuticals Company Profile

500 Arsenal Street

Watertown MA 02472

617 607 0800

www.enanta.com

Industry: Biotechnology

Sector: Healthcare

Enanta Pharmaceuticals

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 676 stocks, only a few dozen will trigger such a signal!

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A pro... ENTA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT